How bone lives and rebuilds: cells, signals, and remodeling
A reference on the biology behind osseointegration — bone structure, the three resident cells, the RANKL/RANK/OPG axis that balances resorption and formation, and the modeling/remodeling cycle that maintains bone around an implant.
Bone is a living, self-renewing tissue. Its architecture, three cell types, and a master signaling axis determine how it responds to an implant and to mechanical load.
Architecture
Cortical vs. trabecular
Cortical (compact): dense outer shell; ~80% of skeletal mass
Trabecular (cancellous): spongy lattice, high surface area
Trabecular bone is metabolically more active
Ratio drives primary stability at placement
Cells
The three bone cells
Osteoblast: builds matrix (osteoid)
Osteoclast: resorbs mineralized bone
Osteocyte: embedded mechanosensor
Their balance sets net bone gain or loss
Signaling
RANKL / RANK / OPG
RANKL (on osteoblasts) binds RANK on osteoclast precursors → resorption
OPG is a decoy receptor that blocks RANKL
RANKL:OPG ratio tunes bone turnover
Target of antiresorptive drugs (e.g., denosumab)
Process
Modeling vs. remodeling
Modeling: shaping — formation and resorption on different surfaces
Remodeling: coupled renewal at the same site
Load (Frost's mechanostat) governs both
Maintains strength and repairs microdamage
02 — Concept selector
Tap a cell or process to see detail
Select a bone cell or the remodeling cycle to read its role. The remodeling sequence runs in a fixed order: activation → resorption → reversal → formation → mineralization.
The remodeling cycle proceeds through ordered phases at a basic multicellular unit (BMU). Formation takes substantially longer than resorption.
Phase
Lead cell
What happens
Approx. duration
Activation
Lining cells / osteocytes
Signal recruits osteoclast precursors to the site
Days
Resorption
Osteoclast
Mineralized bone is dissolved, forming a cavity
~1–3 weeks
Reversal
Reversal cells
Coupling of resorption to formation; surface prepared
~1–2 weeks
Formation
Osteoblast
New osteoid laid down to fill the cavity
~3–4 months
Mineralization
Osteoblast / osteocyte
Osteoid mineralizes; cycle returns to quiescence
Months (full cycle ~4–6 mo)
Note: Some physiologic crestal bone remodeling around an implant after placement and abutment connection is expected; modest early crestal change reflects normal adaptation rather than disease, and steady-state marginal bone levels are a key longevity criterion.
Reference
Sources & clinical disclaimer
For licensed clinicians — educational use only. This page summarizes published basic-science literature and is not a substitute for individual clinical judgment or the standard of care in your jurisdiction. Cycle durations are population averages and vary with site, age, and systemic factors.
Kenkre JS, Bassett JHD. The bone remodelling cycle. Ann Clin Biochem. 2018;55(3):308–327.
Frost HM. Bone's mechanostat: a 2003 update. Anat Rec A Discov Mol Cell Evol Biol. 2003;275(2):1081–1101.
Albrektsson T, Chrcanovic B, Östman PO, Sennerby L. Initial and long-term crestal bone responses to modern dental implants. Periodontol 2000. 2017;73(1):41–50.
Last reviewed: June 2026 · Next review due: June 2027 · Version 1.0
Self-Test
Self-Test
Switch between board-style single-best-answer questions and oral-defense prompts. Commit to an answer before revealing.
1. A patient on long-term denosumab is being assessed for an implant. Denosumab is a monoclonal antibody against RANKL; mechanistically, what is its direct effect on the RANKL/RANK/OPG axis?
B is correct. Denosumab functions as an OPG-mimetic decoy: it binds RANKL and prevents RANKL–RANK engagement, so osteoclast precursors cannot mature, and resorption is suppressed. A and C describe the opposite (pro-resorptive) effect; D is an osteoblast action unrelated to this antibody.
2. In the bone remodeling sequence at a basic multicellular unit (BMU), formation is the rate-limiting, longest phase. Which ordering and relative timing is correct?
B is correct. The fixed sequence is activation → resorption → reversal → formation → mineralization. Resorption is brief (~1–3 weeks) while osteoblastic formation is the long limb (~3–4 months), giving a full cycle of roughly 4–6 months. The other options invert the order or the durations.
3. You place an implant in the posterior maxilla (predominantly fine trabecular bone) versus the anterior mandible (dense cortical bone). How does the cortical:trabecular ratio bear on the biology you expect?
B is correct. Trabecular (cancellous) bone has high surface area, greater vascularity, and higher metabolic/turnover activity, but its lattice yields lower primary mechanical stability. Dense cortical bone gives strong primary stability but is less vascular and turns over more slowly — the reason posterior maxilla is the harder healing site.
4. The osteocyte is the most abundant bone cell. Which statement best captures its central role in deciding where remodeling is activated?
C is correct. Osteocytes are former osteoblasts trapped in lacunae; via their canalicular network they sense mechanical strain and microdamage and orchestrate the activation step — the cellular basis of Frost's mechanostat. A describes osteoblasts, B describes osteoclasts, and D describes the osteoclast (monocyte/macrophage) lineage.
1. Explain the RANKL/RANK/OPG axis and justify why the RANKL:OPG ratio — not any single molecule — is the key determinant of net bone turnover around an implant.
Model answer. Osteoblasts and stromal cells express RANKL, the "go" signal; it binds RANK on osteoclast precursors to drive their maturation and resorptive activity. The same osteoblast lineage secretes OPG, a soluble decoy that binds RANKL and blocks it — the "stop" signal. Because OPG competes for the identical ligand, the biologically meaningful variable is the RANKL:OPG ratio: a high ratio favors osteoclastogenesis and resorption (e.g., chronic peri-implant inflammation driving marginal bone loss), while a low ratio favors bone preservation. This is why the axis is the therapeutic target of antiresorptives such as denosumab.
Examiner follow-ups:
How does inflammation (e.g., peri-implantitis) shift this ratio?
Where does denosumab act, and what is its clinical caution for implant patients?
How do osteocytes feed into RANKL expression?
2. Walk the examiner through the remodeling sequence at a BMU, naming the lead cell of each phase, and defend why formation taking far longer than resorption matters clinically.
Model answer. The cycle runs in a fixed order: activation (lining cells/osteocytes recruit precursors), resorption (osteoclasts excavate a cavity, ~1–3 weeks), reversal (resorption is coupled to formation and the surface is prepared, ~1–2 weeks), formation (osteoblasts deposit osteoid, ~3–4 months), and mineralization (osteoid mineralizes, returning the BMU to quiescence). The full cycle is ~4–6 months. Clinically, because resorption is fast but formation is slow, any transient surge in resorption — or a stimulus that uncouples the two — produces a temporary deficit before new bone catches up. This asymmetry underlies the early stability dip and explains why antiresorptive-altered or inflamed bone is biased toward net loss.
Examiner follow-ups:
What couples resorption to formation in the reversal phase?
How does this asymmetry relate to the implant stability dip?
Modeling vs remodeling — how do they differ?
3. Compare cortical and trabecular bone and justify why some early crestal remodeling around an implant should be interpreted as physiologic adaptation rather than disease.
Model answer. Cortical (compact) bone is the dense outer shell carrying most skeletal mass; it provides strong primary stability but is less vascular and turns over slowly. Trabecular (cancellous) bone is a spongy, high-surface-area lattice that is more vascular and metabolically active but mechanically weaker — so the local ratio drives both primary stability and healing speed. After placement and abutment connection, the crest is exposed to a new loading and biologic environment; the bone remodels to a new steady state, and modest early crestal change reflects normal adaptation (modeling/remodeling under Frost's mechanostat). The relevant longevity criterion is stable marginal bone levels over time, not the absence of any early change — progressive, ongoing loss is what signals disease.
Examiner follow-ups:
What magnitude of first-year crestal change is generally considered acceptable?
How would you distinguish physiologic remodeling from peri-implantitis?
How does bone density (D1–D4) influence your protocol?